[MedPage Today] Shorter TB Regimen Matched Standard Care in Rifampicin-Resistant Disease

24 June 2026

MedPage Today news story

The Phase III BEAT TB trial showed that a shorter, 6-month, all-oral treatment regimen (consisting of bedaquiline, delamanid, linezolid, and levofloxacin or clofazimine or both) demonstrated noninferiority to the longer 9-month standard-of-care regimen for patients with pulmonary rifampicin-resistant TB.

Published in the New England Journal of Medicine (NEJM), the study confirmed that this new, simplified regimen can be safely utilized across entire households, including children and pregnant or breastfeeding women, expanding vital treatment options for these vulnerable populations.

Read the full news story here.

 

Source: MedPage Today

---

SEE ALSO:

• University of the Witwatersrand: South Africa’s TB Research Changes Global Medical Practice
• GroundUp: Important Advance in TB Treatment
• The Clinical Trial Vanguard: The 6-Month RR-TB Trial the FDA Should Be Studying as a Pragmatic Design Blueprint